Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Consolidation and maintenance rituximab therapy in chronic lymphocytic leukemia.

× No keyword cloud information.

15 in total

1. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).

Authors: U Winkler; M Jensen; O Manzke; H Schulz; V Diehl; A Engert
Journal: Blood Date: 1999-10-01 Impact factor: 22.113

2. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.

Authors: John D Hainsworth; Sharlene Litchy; Don W Shaffer; Van L Lackey; Manuel Grimaldi; F Anthony Greco
Journal: J Clin Oncol Date: 2005-01-18 Impact factor: 44.544

3. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

Authors: Barbara F Eichhorst; Raymonde Busch; Georg Hopfinger; Rita Pasold; Manfred Hensel; Cordelia Steinbrecher; Siegfried Siehl; Ulrich Jäger; Manuela Bergmann; Stephan Stilgenbauer; Carmen Schweighofer; Clemens M Wendtner; Hartmut Döhner; Günter Brittinger; Bertold Emmerich; Michael Hallek
Journal: Blood Date: 2005-10-11 Impact factor: 22.113

4. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.

Authors: William Wierda; Susan O'Brien; Sijin Wen; Stefan Faderl; Guillermo Garcia-Manero; Deborah Thomas; Kim-Anh Do; Jorge Cortes; Charles Koller; Miloslav Beran; Alessandra Ferrajoli; Francis Giles; Susan Lerner; Maher Albitar; Hagop Kantarjian; Michael Keating
Journal: J Clin Oncol Date: 2005-03-14 Impact factor: 44.544

5. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.

Authors: K R Rai; B L Peterson; F R Appelbaum; J Kolitz; L Elias; L Shepherd; J Hines; G A Threatte; R A Larson; B D Cheson; C A Schiffer
Journal: N Engl J Med Date: 2000-12-14 Impact factor: 91.245

6. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

Authors: Ian W Flinn; Donna S Neuberg; Michael R Grever; Gordon W Dewald; John M Bennett; Elisabeth M Paietta; Mohamad A Hussein; Frederick R Appelbaum; Richard A Larson; Dennis F Moore; Martin S Tallman
Journal: J Clin Oncol Date: 2007-02-05 Impact factor: 44.544

7. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

Authors: John C Byrd; Kanti Rai; Bercedis L Peterson; Frederick R Appelbaum; Vicki A Morrison; Jonathan E Kolitz; Lois Shepherd; John D Hines; Charles A Schiffer; Richard A Larson
Journal: Blood Date: 2004-05-11 Impact factor: 22.113

8. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

Authors: John C Byrd; Bercedis L Peterson; Vicki A Morrison; Kathleen Park; Robert Jacobson; Eva Hoke; James W Vardiman; Kanti Rai; Charles A Schiffer; Richard A Larson
Journal: Blood Date: 2002-07-05 Impact factor: 22.113

9. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

Authors: D Catovsky; S Richards; E Matutes; D Oscier; Mjs Dyer; R F Bezares; A R Pettitt; T Hamblin; D W Milligan; J A Child; M S Hamilton; C E Dearden; A G Smith; A G Bosanquet; Z Davis; V Brito-Babapulle; M Else; R Wade; P Hillmen
Journal: Lancet Date: 2007-07-21 Impact factor: 79.321

10. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.

Authors: Nicole Lamanna; Matt Kalaycio; Peter Maslak; Joseph G Jurcic; Mark Heaney; Renier Brentjens; Andrew D Zelenetz; Denise Horgan; Alison Gencarelli; Katherine S Panageas; David A Scheinberg; Mark A Weiss
Journal: J Clin Oncol Date: 2006-03-06 Impact factor: 50.717